Key result
Age over 65 is linked to ~180% greater bleeding risk in warfarin-treated patients.
Why the study?
Bleeding is the most frequent and restrictive complication of warfarin therapy, and the study aimed to compare bleeding risk factors between patients with and without warfarin-related bleeding.
What are the clinical and demographic risk factors associated with warfarin-related bleeding?
Case-Control (n=201)
No
What are the clinical and demographic risk factors associated with warfarin-related bleeding?
Age over 65, presence of comorbid diseases, history of stroke, and lower education level are significant risk factors for warfarin-associated bleeding, highlighting the need for targeted monitoring and patient education.
Answers are grounded in this paper and cite their sources.
May support closer monitoring of older warfarin patients with comorbidities; leaves open prospective validation in larger cohorts.
Objectives: Warfarin is the most commonly used oral agent for long-term anticoagulation.Nevertheless, bleeding is the most frequent side effect of warfarin, increasing mortality and morbidity and thereby restricting its use.Risk factors for bleeding include age, comorbid diseases, use of drugs that may interact with warfarin, and previous history of stroke or gastrointestinal bleeding.Using a questionnaire-based method, this study aimed to compare the risk of bleeding in two groups of warfarin users with and without a history of warfarinrelated bleeding. Materials and Methods:A total of 201 patients, including 100 who had bleeding during warfarin use in our outpatient clinic and 101 patients who were followed up with the international normalization rate, were included in the study.Risk factors in warfarin-related bleeding were evaluated by the researcher with a questionnaire created as a result of the literature review.Data were statistically analyzed. Results:The prevalence of bleeding was 2.8 times higher in patients aged 65 years and older (confidence interval: 1.40-5.56)and 5.6 times higher in patients with comorbid diseases (confidence interval: 1.376-22.770).A history of stroke increased major bleeding 3.2 fold (confidence interval: 1.08-9.61).We also observed that lack of education might be a risk factor for warfarin-related bleeding. Conclusion:We believe that older patients under warfarin treatment should be informed according to their education status, and their medications and comorbid diseases should be monitored regularly by the same centers.
No takes yet. Share an insight, caveat, or question.
Özgenel et al. (2023) conducted a case-control in Warfarin-associated bleeding (n=201). Age ≥65 years vs. Age <65 years was evaluated on Warfarin-associated bleeding (OR 2.8, 95% CI 1.409-5.563, p=0.05). In patients treated with warfarin, being 65 years of age or older and having comorbid diseases increased the risk of bleeding by 2.8-fold and 5.6-fold, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: